NCT07626450 HBO After Thrombectomy for AIS With LVO
| NCT ID | NCT07626450 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Tiantan Hospital |
| Condition | Acute Ischemic Stroke From Large Vessel Occlusion |
| Study Type | INTERVENTIONAL |
| Enrollment | 420 participants |
| Start Date | 2026-06 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 420 participants in total. It began in 2026-06 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this RCT trial is to evaluate whether the sequential hyperbaric oxygen therapy can improve the 90-day functional outcome in patients with acute large vessel occlusion ischemic stroke after endovascular treatment.
Eligibility Criteria
Inclusion Criteria: 1. Age 18\~80 years; 2. Clinically diagnosed as acute large vessel occlusive ischemic stroke, suitable for and received endovascular treatment according to current clinical guidelines; 3. The onset of stroke or the last normal time to the time of endovascular treatment ≤ 24 hours; 4. Pre-stroke mRS score of 0 or 1; 5. Baseline NIHSS score before endovascular treatment ≥ 6 points in the anterior circulation or ≥10 points in the posterior circulation; 6. CTA, MRA, or DSA angiography before endovascular treatment confirmed occlusion of large vessels (internal carotid artery, middle cerebral artery M1 segment, basilar artery), consistent with symptoms and signs; 7. The corresponding anterior circulation ASPECTS score or posterior circulation pc-ASPECTS score ≥ 6 points; 8. The pontine midbrain index (PMI) of patients with acute basilar artery occlusion ≤3; 9. Patients or their family members sign the informed consent form. Exclusion Criteria: 1. Patients with extensive bleeding or severe increase in infarct area, midline displacement (\>0.5cm), etc. during endovascular treatment, who plan to undergo bone valve decompression or ventricular drainage; 2. Known bleeding risk factors, including coagulation factor deficiency, or receiving anticoagulant therapy, INR\>3.0 or APTT \> 3 times normal or platelet count less than 50×10⁹/L; 3. Severe hepatic or renal dysfunction (severe hepatic dysfunction refers to ALT or AST \> 3 times the upper limit of the normal range, severe renal dysfunction refers to serum creatinine Cr \>1.5 times the upper limit of the normal range); 4. Females of pregnancy, or positive pregnancy test prior to randomization; 5. Severe persistent and medication-uncontrollable hypertension (systolic blood \> 185 mmHg or diastolic blood \> 110 mmHg) 6. Baseline blood glucose of \<50 mg/dL (2.78 mmol/L) or \>400 mg/dL (22.20 mmol/L); 7. The oxygen required to maintain 95% of peripheral arterial oxygen saturation (SaO2) under the current medium-term management guidelines \> 3L/min; 8. End-stage disease other than the nervous system, life expectancy \< 90 days; 9. Participating in other drug or medical device clinical trials; 10. CT or MR suggests intracranial tumors (other than meningiomas) or other high-risk intracranial vascular malformations; 11. Patients with anemia, polycythemia or other conditions requiring urgent oxygen; 12. Unable to cooperate with hyperbaric oxygen therapy, or have other diseases that are not suitable for hyperbaric oxygen therapy (such as active/chronic obstructive pulmonary disease, acute respiratory distress syndrome, tension pneumothorax, tension pneumocephalus, etc.).
Contact & Investigator
Ning Ma, MD
PRINCIPAL INVESTIGATOR
Beijing Tiantan Hospital
Frequently Asked Questions
Who can join the NCT07626450 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Acute Ischemic Stroke From Large Vessel Occlusion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07626450 currently recruiting?
Yes, NCT07626450 is actively recruiting participants. Contact the research team at maning_03@hotmail.com for enrollment information.
Where is the NCT07626450 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07626450 clinical trial?
NCT07626450 is sponsored by Beijing Tiantan Hospital. The principal investigator is Ning Ma, MD at Beijing Tiantan Hospital. The trial plans to enroll 420 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.